ALUR · Allurion Technologies, Inc. · Webcasts, Transcripts & Audio
$0.39
-0.29 (-42.62%)
At close · Mar 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because the amount and timing of such financings are uncertain, the Company has concluded that management’s plans do not alleviate substantial doubt about its ability to continue as a going concern for a reasonable period of time.”View the 10-Q filed May 15, 2026
Market Cap
$2.01M
Shares
1.00M
Volume · Mar 9
392.2K
Avg daily vol (3M)
—
Allurion Technologies, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Allurion Technologies, Inc. (ALUR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY25 · Q3
2025-11-12
Allurion Technologies, Inc. (ALUR) Q3 2025 Earnings Call Transcript
Confident tone
Strategic pivot to combination therapy with GLP-1s
U.S. market launch preparation
FDA approval progress
Revenue
$2.66M
▼ 50.5% YoY Diluted EPS
$-1.53
▼ 145% YoY Gross margin
49.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Allurion Technologies, Inc. (ALUR) Q2 2025 Earnings Call Transcript
Positive tone
R&D pipeline and GLP-1 drug-eluting balloon
Strategic pivot to combination therapy with low-dose GLP-1s
Operating expense reduction and restructuring
Revenue
$3.38M
▼ 71.3% YoY Diluted EPS
$-1.28
Gross margin
73.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Allurion Technologies, Inc. (ALUR) Q1 2025 Earnings Call Transcript
Confident tone
GLP-1 Combination Strategy
FDA Approval Pathway
Path to Profitability
Revenue
$5.58M
▼ 40.5% YoY Diluted EPS
$-0.31
▼ 132.3% YoY Gross margin
74.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-26
Allurion Technologies, Inc. (ALUR) Q4 2024 Earnings Call
Revenue
$5.59M*
▼ 32.1% YoY Gross margin
45.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Allurion Technologies, Inc. (ALUR) Q3 2024 Earnings Call Transcript
Positive tone
Q3 Financial Results and France Recall
GLP-1 Market Impact and Combination Therapy
U.S. FDA Approval and Launch
Revenue
$5.37M
▼ 70.5% YoY Diluted EPS
$3.40
Gross margin
58.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Allurion Technologies, Inc. (ALUR) Q2 2024 Earnings Call Transcript
Balanced tone
France ANSM suspension
GLP-1 competition and positioning
Procedure volume and demand
Revenue
$11.77M
▼ 9.2% YoY Diluted EPS
$-4.34
Gross margin
76.4%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Allurion Technologies, Inc. (ALUR) Q1 2024 Earnings Call Transcript
Confident tone
Revenue and 2024 guidance
Virtual Care Suite / B2B SaaS
Geographic expansion and AUDACITY FDA trial
Revenue
$9.39M
▼ 33.3% YoY Diluted EPS
$0.96
Gross margin
73.2%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Allurion Technologies, Inc. (ALUR) Q4 2023 Earnings Call Transcript
Positive tone
GLP-1 drugs as opportunity and headwind
Cost reduction and cash burn
Audacity FDA trial and PMA
Revenue
$8.24M*
Gross margin
78.1%
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Allurion Technologies, Inc. (ALUR) Q3 2023 Earnings Call Transcript
Revenue
$18.20M
▲ 13.3% YoY Diluted EPS
$-13.56
Gross margin
76.7%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Showing 1–9 of 9 webcasts